Eli Lilly doubles down on in vivo with $7bn Kelonia buyout
Lilly now has a lentiviral and LNP-based platform for in vivo delivery under its belt, which analyst Jack Cuthbertson says will give the company a broader chance for success.
Accelerate decision-making with data-led confidence
Combine proprietary data, human expertise, and purpose-built AI to uncover insights and accelerate better business decisions.
Discover our solutions
CinnaGen Enters EU Market with EMA Approval for Zandoriah®
Eli Lilly and NVIDIA to build pharma’s “most powerful” supercomputer
Huawei’s three key steps to drive industrial intelligence forward and unleash AI’s full potential
First responders see AI and other advanced tech as essential